Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5

Janis T Lee1, Gillian M Air

  • 1Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, 73104, USA.

Virology
|November 22, 2005
PubMed

Insights

Influenza virus neuraminidase (NA) mutations can evade antibody binding. Key amino acid interactions in the NA-Mem5 antibody complex were identified, revealing sites prone to mutations that drive viral escape and antigenic drift.

Area of Science:

  • Virology
  • Immunology
  • Structural Biology

Background:

  • Influenza viruses continuously evolve to escape host immunity.
  • Neuraminidase (NA) is a key surface protein and a target for neutralizing antibodies.
  • Mutations in NA can alter antibody binding, leading to viral escape.

Purpose of the Study:

  • To investigate the contribution of individual amino acids in influenza A H3N2 neuraminidase (NA) to the stability of its complex with the monoclonal antibody Mem5.
  • To identify critical interactions within the NA epitope that are susceptible to mutations driving antibody escape.

Main Methods:

  • Site-directed mutagenesis of specific amino acids in the H3N2 neuraminidase (NA).
  • Quantification of antibody binding affinity using NA inhibition assays and ELISA.
  • Structural analysis of antibody-epitope interactions.

Main Results:

  • Mutations at E199A, E199Q, and K221R abrogated binding of the Mem5 antibody to NA.
  • Most other mutations resulted in reduced binding affinity without complete loss of inhibition.
  • The Mem5 epitope is characterized by a few high-energy interactions, unlike broader epitopes.

Conclusions:

  • Specific amino acid residues in the NA epitope are critical for high-affinity antibody binding.
  • Energetically dominant interactions in antigenic sites are prone to mutations, facilitating influenza virus immune escape.
  • Understanding these interactions aids in predicting antigenic drift and developing more effective influenza vaccines.